BRTX BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.…
Industry Peers
BiotechnologyKey Statistics
About BioRestorative Therapies (NASDAQ: BRTX)
›
BioRestorative Therapies (NASDAQ: BRTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 1.490 USD on 13 November 2026, down 94.7% over 52 weeks. Its 52-week range is 1.310 USD to 28.99 USD: the price is 94.9% below the high and 13.7% above the low.
Its market capitalisation is 2.06M USD.
BioRestorative Therapies reports revenue down 7.3% year over year.
It holds more cash than debt, a net cash position of 3.56M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.